Well deserved recognition for a true legend @DrHKantarjian So glad to be a part of his #Leukemia team. He is phenomenal.. a true inspiration for the junior faculty.
We are proud to celebrate our Dr. Hagop Kantarjian receiving the prestigious David A. Karnofsky Memorial Award from @ASCO for his contributions to leukemia care and research. @DrHKantarjian#ASCO23#EndCancer [1/3]
Led by our own Dr. Verstovsek of @MDAndersonNews#Leukemia, important Ph3 study MOMENTUM: Momelotinib vs danazol resulted in clinically significant improvements in MF-associated anemia+sxs+spleen response+favorable safety.
https://t.co/j1dR6VRi9E @TheLancet#MPNSM
@ssrajamouli might like how his magnus opus is being used in medical field. Aza+Ben synergism, multiple courses needed, some soldiers hide and come back #loveIt#leusm
#hematology predictions for 2023: 1) single-board #classicalhematology will become fastest growing subspecialty in internal medicine. Thanks #HFFTP; 2) #bmt: Indications for BMT will decline for malignant disease...
I believe it is important in medicine and in life to understand the history to evaluate the present and to shape the future.
Therefore, a short ����on the early history of myelofibrosis.
#MedTwitter #MedStudentTwitter #mpnsm
ASH has adopted the term "classical hematology," in place of what was formerly referred to as "benign" or "nonmalignant." Discoveries within #classicalheme have significantly advanced the field & continue to better the lives of those living with non-cancerous blood disorders.
1/2
Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL.
Jabbour, Short, Kantarjian of @MDAndersonNews#Leukemia https://t.co/gKPyzpRiiI via @TheLancetHaem#leusm
Happy #Diwali2022. A festival without borders as we celebrate the victory of good over evil, light over dark and resilience over suffering. May the Festival of Lights remove any darkness in our lives. #endcancer#celebration